Hypereosinophilic syndrome
MONDO:0015691Hypereosinophilic syndrome (HES) constitutes a rare and heterogeneous group of disorders, defined as persistent and marked blood eosinophilia and/or tissue eosinophilia associated with a wide range of clinical manifestations reflecting eosinophil-induced tissue/organ damage.
Also known as: HES, hypereosinophilic disease, hypereosinophilic disorder, hypereosinophilic syndrome, eosinophilia
54 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New drug shows promise in reversing lung damage from severe asthma
Disease control OngoingThis study tests whether benralizumab can improve lung structure and function in people with severe eosinophilic asthma who still have symptoms despite standard treatments. About 75 adults aged 18-70 will receive either the drug or a placebo for 48 weeks, followed by a 4-week che…
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Could a short course of steroids calm a dangerous heart rhythm?
Disease control ENROLLING_BY_INVITATIONThis trial tests whether an 8-week course of the immunosuppressive drug prednisone can reduce episodes of ventricular tachycardia (a potentially fatal fast heart rhythm) and improve heart function in people with non-ischemic cardiomyopathy and confirmed heart inflammation. Partic…
Phase: PHASE4 • Sponsor: Roderick Tung • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New hope for kids with severe asthma: drug aims to cut attacks
Disease control OngoingThis study tests whether benralizumab, an injected drug, can reduce asthma attacks in children aged 6 to 17 with severe eosinophilic asthma. About 200 participants will receive either benralizumab or a placebo, and researchers will track how long it takes for their first asthma f…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug cocktail shows promise for Hard-to-Treat leukemia
Disease control OngoingThis early-phase trial tests a combination of three drugs—azacitidine, venetoclax, and pevonedistat—in adults newly diagnosed with a challenging form of acute myeloid leukemia (AML). The goal is to find the best dose and see if the combo can improve remission rates. About 40 part…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug aims to tame rare blood disorder flares
Disease control OngoingThis Phase 3 study tests whether benralizumab, a biologic injection given every 4 weeks, can reduce flares in people with hypereosinophilic syndrome (HES), a rare condition where too many eosinophils cause organ damage. About 134 patients aged 12 and older will receive either ben…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Cancer drug shows promise in taming rare blood disorder
Disease control OngoingThis study tests whether the drug imatinib (Gleevec) can safely lower high levels of eosinophils (a type of white blood cell) in people with hypereosinophilic syndrome (HES), a rare condition that can damage organs. About 70 adults and children (age 2 and up) with a specific form…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New pill could ease severe asthma attacks
Disease control OngoingThis Phase 3 trial tests dexpramipexole, an oral tablet, as an add-on treatment for people with eosinophilic asthma that is not well controlled. About 600 participants aged 12 and older will receive either the drug or a placebo for 24 weeks. The study measures improvements in lun…
Phase: PHASE3 • Sponsor: Areteia Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 14:18 UTC
-
Super MRI could spot hidden heart damage
Diagnosis OngoingThis study tests whether a new, more powerful 7 Tesla MRI can better detect scarring and swelling in the heart muscle of people with cardiomyopathy. Researchers will scan 13 adults aged 20-70 to see if the higher-resolution images improve diagnosis. The goal is to see if this adv…
Sponsor: University of Pennsylvania • Aim: Diagnosis
Last updated Jun 27, 2026 09:02 UTC
-
Severe asthma drug may boost daily steps, study hopes
Knowledge-focused OngoingThis study looks at whether mepolizumab, a drug already used to reduce asthma attacks, can also improve physical activity and exercise tolerance in people with severe asthma. Researchers will track daily steps and activity levels in 62 adults over six months. The goal is to see i…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New study digs into how mepolizumab changes nose bacteria and genes in asthma patients
Knowledge-focused OngoingThis study tracks 40 people with nasal polyps and severe asthma who are taking mepolizumab, a drug that reduces inflammation. Researchers collect nose, blood, and sputum samples before treatment and at 3, 6, and 12 months to see how the drug affects symptoms, nose bacteria, and g…
Sponsor: National and Kapodistrian University of Athens • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Proteomics may unlock key clues to mepolizumab success in rare lung disease
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to find biological markers in blood, saliva, and sputum that can predict how well patients with EGPA (a rare inflammatory disease) and severe asthma respond to the drug mepolizumab. Researchers will analyze proteins in these samples before and after treatment to u…
Phase: PHASE4 • Sponsor: Azienda Ospedaliero Universitaria di Cagliari • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC